Abstract
Fourteen patients with Philadelphia chromosome (Ph1-positive chronic myelogenous leukemia (CML) in stable-phase have been treated with recombinant human interferon-gamma (IFN-gamma). The interferon was given as daily subcutaneous injection, five times per week. Doses were escalated in individual patients in 4-week intervals starting from 0.1 mg/m2 to 0.5 mg/m2 (maximum safely tolerated dose) of body-surface area. The most common side effects were constitutional symptomes, including fever, chills, fatigue, myalgia, and night sweats. Serum assays for antiinterferon antibodies were negative in all patients. A partial response (decrease of WBC and platelet counts by more than 50%) was seen in only one patient, without achieving suppression of Ph1-positive cells as assessed by cytogenetic and c-abl/bcr analysis. Thirteen patients failed to show sustained antileukemic response to IFN-gamma. These data demonstrate that the use of IFN-gamma is not effective in inducing hematologic remissions in patients with stable-phase CML in the treatment schedule.
Supported in part by the Deutsche Forschungsgemeinschaft (He 1380-2-1)
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Stryckmans PA (1980) Treatment of chronic myeloid leukemia. Annu Rev Med 31: 159
Goldman JM, Apperley JF, Jones L et al (1986) Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 314: 202
Pestka S (1986) Interferon: a decade of accomplishments, foundations of the future in research and therapy. Sem Hematol 23 (Suppl 1): 27
Quesada JR, Reuben J, Manning JT, et al. (1984) Alpha interferon for induction of remission in hairy cell leukemia. N Engl J Med 310: 15
Talpaz M, Kantarjian J, McCredie K, et al. (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 314–1065
Broxmeyer HE, Lu L, Platzer E, et al. (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential, erythroid, and granulocyte-mac-rophage progenitor cells. J Immunol 131: 1300
Basham T, Merigan TC (1982) Immunoregulation by gamma-interferon. Nature 299: 778
Griffin JD, Sabbath KD, Herrmann F et al. (1985) Differential expression of HLA-DR antigens in subsets of human CFU-GM. Blood 66: 788
Cannistra SA, Herrmann F, Davis R, et al. (1986) Relationship between HLA-DR expression by normal myeloid progenitor cells and inhibition of colony growth by prostaglandin E. Implication for prostaglandin E resistance in chronic myeloid leukemia. J Clin Invest 77: 13
Herrmann F, Cannistra SA, Levine H, et al. (1985) Expression of IL-2 receptors and binding of IL-2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 162: 1111
Seabright M (1971) A rapid banding technique for human chromosomes. Lancet 2: 971
Southern E (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98: 503
Chang TW, McKinney S, Liu S, et al. (1984) Use of monoclonal antibodies as sensitive and specific probes for biologically active human interferon-gamma. Proc Natl Acad Sci USA 81: 5219
Vadhan-Raj S, Al-Katib A, Bhalli R, et al. (1986) Phase I trial of recombinant interferon gamma in cancer patients. J Clin Oncol 4, 137
Kurzrock R, Quesada JR, Talpaz M, et al. (1986) Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. J Clin Oncol 4, 1101
Herrmann F, Lindemann A, Oster W, Mertelsmann R (1987) In vitro effect of recombinant human tumor necrosis factor-alpha and interferon-gamma on normal and leukemic myelopoiesis. This volume
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Herrmann, F., Lindemann, A., Otto, J., Mertelsmann, R. (1988). In Vivo Effects of Interferon-gamma in Chronic Myelogenous Leukemia. In: Huhn, D., Hellriegel, K.P., Niederle, N. (eds) Chronic Myelocytic Leukemia and Interferon. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73526-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-73526-4_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19067-7
Online ISBN: 978-3-642-73526-4
eBook Packages: Springer Book Archive